Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (71-80 of 1,122) with videos related to

Pageof 113
Sort By:
BJU International|October 18, 2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management optionsBlair Egerdie, Fred Saad
Urology|February 25, 2015
Current and Emerging Immunotherapies for Castration-resistant Prostate CancerFred Saad, Kurt Miller
Urology|November 9, 2010
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancerFred Saad, James Eastham
Seminars in Oncology|August 5, 2010
Maintaining bone health in prostate cancer throughout the disease continuumFred Saad, James Eastham
Current Opinion in Supportive and Palliative Care|October 26, 2021
Editorial: Patient selection in urologic oncology - one size does not fit allAndrea Kokorovic, Fred Saad
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2017
New research in prostate cancer, ASCO-GU 2017Kim Chi, Fred Saad
Cancer Treatment Reviews|December 18, 2009
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerFred Saad, Allan Lipton
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancersFred Saad, Peter Mulders
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 18, 2013
Optimal management of patients receiving cabazitaxel-based chemotherapyCatherine Sperlich, Fred Saad
Pageof 113

Showing results (71-80 of 1,122) with videos related to

Sort By:
Pageof 113
BJU International|October 18, 2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management optionsBlair Egerdie, Fred Saad
Urology|February 25, 2015
Current and Emerging Immunotherapies for Castration-resistant Prostate CancerFred Saad, Kurt Miller
Urology|November 9, 2010
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancerFred Saad, James Eastham
Seminars in Oncology|August 5, 2010
Maintaining bone health in prostate cancer throughout the disease continuumFred Saad, James Eastham
Current Opinion in Supportive and Palliative Care|October 26, 2021
Editorial: Patient selection in urologic oncology - one size does not fit allAndrea Kokorovic, Fred Saad
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2017
New research in prostate cancer, ASCO-GU 2017Kim Chi, Fred Saad
Cancer Treatment Reviews|December 18, 2009
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerFred Saad, Allan Lipton
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancersFred Saad, Peter Mulders
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 18, 2013
Optimal management of patients receiving cabazitaxel-based chemotherapyCatherine Sperlich, Fred Saad
Pageof 113